Company profile

Veradermics, Incorporated

Pipeline5 assets

VDPHL01VDPHL01 / Small molecule / Dermatology
Androgenetic Alopecia (Pattern Hair Loss)
VDAAVDAA / Topical small molecule / Dermatology
Alopecia Areata
VDADVDAD / Dermatology
Atopic Dermatitis
VDMCVDMC / Dermatology
Molluscum Contagiosum
VDMN-21VDMN-21 / Immune stimulatory / Microarray / Dermatology
Warts

Latest news14 items

May 27, 2026

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research

NEW HAVEN, Conn. --(BUSINESS WIRE)--May 27, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 ‘302’ Study of

Presentation / Abstract • Phase 2/3Poster presentation Sat, May 30, 2026, 3:00 PM KST

May 14, 2026

Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium

NEW HAVEN, Conn. --(BUSINESS WIRE)--May 14, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that two E-posters will be presented at the 2026

Presentation / Abstract • Phase 2E-poster presentation Thu, May 14, 2026

May 12, 2026

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Positive topline results from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years Upsized IPO and follow-on financing generated approximately $766.8 million in aggregate gross proceeds; pro forma cash expected

Trial Results • Phase 2/3Study 302 Part A topline results Wed, Apr 1, 2026

Apr 29, 2026

Veradermics Announces Pricing of Upsized Public Offering and Private Placement

NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 29, 2026-- Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the pricing of its upsized public

Apr 27, 2026

Veradermics Announces Launch of Public Offering

NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 27, 2026-- Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed

Apr 27, 2026

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was

Trial Results • Phase 2/3

Apr 26, 2026

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Conference call will take place on Monday, April 27, 2026 at 8:00 am ET NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 26, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss,

Results Call • Phase 2/3

Mar 30, 2026

Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026 Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss Mark

Enrollment • Phase 3

Mar 18, 2026

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

NEW HAVEN, Conn. --(BUSINESS WIRE)--Mar. 18, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts

Presentation / Abstract • Phase 3

Mar 3, 2026

Veradermics to Participate in Upcoming March Investor Conferences

NEW HAVEN, Conn. --(BUSINESS WIRE)--Mar. 3, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will

Feb 9, 2026

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies Topline data from initial '302' trial anticipated in the first half of 2026; '304' confirmatory study topline data anticipated in the

Enrollment • Phase 3

Feb 5, 2026

Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

NEW HAVEN, Conn. --(BUSINESS WIRE)--Feb. 5, 2026-- Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the

Feb 3, 2026

Veradermics Announces Pricing of Upsized Initial Public Offering

NEW HAVEN, Conn. --(BUSINESS WIRE)--Feb. 3, 2026-- Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the

Dec 11, 2025

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral Minoxidil

Registration-directed program also includes a second Phase 3 trial in males and a Phase 2/3 trial in females with pattern hair loss, which are actively enrolling Full data from ongoing VDPHL01 Phase 2 trial in males and females is expected in 2026; early data in males indicated visible and

Enrollment • Phase 2/3